SRPT Sarepta Therapeutics Inc.

Sarepta Therapeutics Announces Winners of the “Rare Lessons” Lesson Planning Competition

Sarepta Therapeutics Announces Winners of the “Rare Lessons” Lesson Planning Competition

  • The four winning lesson plans are now available on sharemylesson.com
  • Lesson plans showcase creative ways to build awareness of rare disease and to build diversity and inclusion in the classroom

CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the four winners of the Rare Lessons lesson planning competition. Sarepta has granted the winning authors $2,500 each and $2,500 to the educational institution with which each is affiliated. The winning submissions are now available on , and more information about the authors can be found at .

Rare Lessons competition winners and lesson plan titles:

  • Laura Doyle, Atlanta International School, Atlanta, Ga.:
  • Jessica Keogh, West Chester Area School District, Exton, Penn.:
  • Sarah Kesty, Castle Park Middle School, Chula Vista, Calif.:
  • Kaitlin Payne, South Topsail Elementary School, Hampstead, N.C.:

“Each of these lesson plans is unique, but share in their creativity, passion and innovative thinking aimed at building awareness of rare disease and promoting diversity and inclusion within the classroom and community. Though judges were blinded to author identity and background, another remarkable commonality is the recipients’ connections to rare disease, in most cases either living with a rare disease or caring for a loved one with a rare disease,” said Diane Berry, Ph.D., Sarepta’s Senior Vice President of Global Health Policy, Government and Patient Affairs. “We encourage everyone to share the sharemylesson.com links with educators in your lives, take action to start a conversation and increase understanding of rare disease, and ultimately help alleviate feelings of isolation often experienced by children and families having to navigate living with a rare disease. Sarepta congratulates all the winning authors and extends our thanks and appreciation to all contest entrants and the selection committee for generously giving of their time to review the lesson plan submissions.”

This program is intended to promote the development and implementation of educational materials to increase rare disease awareness in the K-12 classroom setting. The competition was open to educators in grades K-12, based in the United States, and actively teaching in an accredited educational institution. A blinded selection committee reviewed and selected the submissions. For the Rare Lessons contest, Sarepta partnered with , a platform that offers broad availability of lesson plans for educators and schools across the country.

About Sarepta Therapeutics

At Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Company’s programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. For more information, please visit  or follow us on , ,  and .

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website at . We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.

Investors:

Ian Estepan, 617-274-4052,

Media:

Tracy Sorrentino, 617-301-8566,



EN
04/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sarepta Therapeutics Inc.

Wedbush Research
  • Wedbush Research
David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Robert Driscoll
  • Thomas Yip
  • Yun Zhong

The Week Ahead in Life Sciences

Arcus Biosciences (RCUS) Feb. 28, 2026: Additional ARC-20 data including activity and biomarker analysis of cas in ccRCCAscendis Pharma (ASND) Feb. 28, 2026: PDUFA date for TransCon CNP for pediatric achondroplasiaBioMarin Pharmaceutical (BMRN) Feb. 28, 2026: PDUFA date for Palynziq for adolescent

Wedbush Research
  • Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TSLA TESLA INC
SRPT SAREPTA THERAPEUTICS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
NFLX NETFLIX INC.
FRX_CN FENNEC PHARMACEUTICALS
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
WVE WAVE LIFE SCIENCES
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
OVID OVID THERAPEUTICS
ISR ISORAY
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
UBER UBER TECHNOLOGIES INC.
GOSS GOSSAMER BIO
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
IDYA INC.
PASG IDEAYA BIOSCIENCES
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
KROS ADICET BIO INC
ZNTL KEROS THERAPEUTICS
BEAM ZENTALIS PHARMACEUTICALS
LRMR BEAM THERAPEUTICS
PRAX LARIMAR THERAPEUTICS INC
U PRAXIS PRECISION MEDICINES
TVTX UNITY SOFTWARE
DASH TRAVERE THERAPEUTICS INC
VRDN DOORDASH
PLTK VIRIDIAN THERAPEUTICS INC
RBLX PLAYTIKA HOLDING
DAWN ROBLOX
STX DAY ONE BIOPHARMACEUTICALS INC
APP SEAGATE TECHNOLOGY HLDGS PLC
GFS APPLOVIN CORP
GMTX GLOBALFOUNDRIES INC
TYRA GEMINI THERAPEUTICS INC
EWTX TYRA BIOSCIENCES INC
SLDB EDGEWISE THERAPEUTICS INC
APGE SOLID BIOSCIENCES INC
DNTH APOGEE THERAPEUTICS INC
CGON DIANTHUS THERAPEUTICS INC
ORKA CG ONCOLOGY INC
BCAX ORUKA THERAPEUTICS INC
ZBIO BICARA THERAPEUTICS INC.
TLX ZENAS BIOPHARMA INC.
MAZE TELIX PHARMACEUTICALS LIMITED
JBIO MAZE THERAPEUTICS INC
JADE BIOSCIENCES INC
David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Robert Driscoll
  • Thomas Yip
  • Yun Zhong

ResearchPool Subscriptions

Get the most out of your insights

Get in touch